Abstract
Irinotecan (Fig. 1), also known as CPT-11, is a semisynthetic derivative of 20(S)camptothecin (1), a pentacyclic alkaloid first identified in extracts of the Chinese shrub Camptotheca acuminata. The mechanism of action of camptothecin has been covered in other chapters of this book and need not be revisited here. However, it is pertinent to point out that CPT-11 itself is only a very weak stabilizer of the cleavable complex formed between DNA and topoisomerase I (TOP-I) and requires conversion to an active metabolite, SN-38 (2). The latter is one of the most potent TOP-I poisons known, which may be a result of the prolonged half-life of interaction with the cleavable complex (3). In vivo, the activation of CPT-11 to SN-38 is carried out by carboxylesterases (4–8). In turn, SN-38 can be conjugated to SN-38 β-glucuronide (9,10). CPT-11 is also metabolized to an aminopentanocarboxylic (APC), metabolite (see Fig. 1), and other minor, mostly inactive, products by cytochrome P450 3A4/5 (11–14).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sawada S, Okajima S, Aiyama R, et al. 1991Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull. 39: 1446–1450.
Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. 1991 Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51:4187–4191.
Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. 1994 Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 86:836–842.
Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. 1991 CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn. 14:341–349.
Rivory LP, Bowles MR, Robert J, Pond SM. 1996 Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol. 52:1103–1111.
Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. 1994 Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull. 17:662–664.
Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. 1997 Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos. 25:1157–1164.
Haaz MC, Rivory LP, Riche C, Robert J. 1997 The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol. 356:257–262.
Atsumi R, Suzuki W, Hakusui H. 1991 Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica. 21:1159–1169.
Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J. 1997 Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol. 80:91–96.
Santos A, Zanetta S, Cresteil T, et al. 2000 Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res. 6:2012–2020.
Haaz MC, Rivory L, Riche C, Vernillet L, Robert J. 1998 Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58:468–472.
Rivory LP, Riou JF, Haaz MC, et al. 1996 Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 56:3689–3694.
Haaz MC, Riche C, Rivory LP, Robert J. 1998 Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxycamptothecine] by human hepatic microsomes. Drug Metab Dispos. 26:769–774.
Rothenberg ML, Cox JV, DeVore RF, et al. 1999 A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 85:786–795.
Rothenberg ML, Eckardt JR, Kuhn JG, et al. 1996 Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 14:1128–1135.
Rougier P, Bugat R, Douillard JY, et al. 1997 Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 15:251–260.
Pitot HC, Wender DB, O’Connell MJ, et al. 1997 Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 15:2910–2919.
Cunningham D, Pyrhonen S, James RD, et al. 1998 Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352: 1413–1418.
Douillard JY, Cunningham D, Roth AD, et al. 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:1041–1047.
Saltz LB, Cox JV, Blanke C, et al. 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med. 343:905–914.
Shimada Y, Yoshino M, Wakui A, et al. 1993 Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 11:909–913.
Shimada Y, Rougier P, Pitot H. 1996 Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer. 32A(Suppl. 3):S13–S17.
Rothenberg ML, Kuhn JG, Schaaf LJ, et al. 1998 Alternative dosing schedules for irinotecan. Oncology. 12:68–71.
Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. 1995 Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 13: 210–221.
Rowinsky EK, Grochow LB, Ettinger DS, et al. 1994 Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54:427–436.
Merrouche Y, Extra JM, Abigerges D, et al. 1997 High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol. 15:1080–1086.
Rothenberg ML, Kuhn JG, Burris HA, et al. 1993 Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 11:2194–2204.
de Forni M, Bugat R, Chabot GG, et al. 1994 Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54:4347–4354.
Tsuda H, Takatsuki K, Ohno R, et al. 1994 Treatment of adult T-cell leukaemialymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br J Cancer. 70:771–774.
Catimel G, Chabot GG, Guastalla JP, et al. 1995 Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol. 6:133–140.
Ohe Y, Sasaki Y, Shinkai T, et al. 1992 Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst. 84:972–974.
Ohno R, Okada K, Masaoka T, et al. 1990 An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 8:1907–1912.
Conti JA, Kemeny NE, Saltz LB, et al. 1996 Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 14:709–715.
Armand JP, Ducreux M, Mahjoubi M, et al. 1995 CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer. 31A:1283–1287.
Abigerges D, Armand JP, Chabot GG, et al. 1994 Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 86:446–449.
Drengler RL, Kuhn JG, Schaaf LJ, et al. 1999 Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol. 17:685–696.
Pitot H, Adjei AA, Reid JM, et al. 2001 A phase I and pharmacokinetic study of a powder-filled capsule (PFC) formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 20:102a.
Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. 1999 Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer. 35: 54–59.
Allen M, Cunningham D, Schmitt C. 1998 The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies. Anti-Cancer Drugs. 9:783–790.
Cunningham D, Glimelius B. 1999 A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol. 26:6–12.
Rougier P, Van Cutsem E, Bajetta E, et al. 1998 Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352: 1407–1412.
Iveson TJ, Hickish T, Schmitt C, Van Cutsem E. 1999 Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer. 35: 1796–1804.
Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. 2000 Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol. 11:157–161.
Schmitt C, Blijham G, Jolain B, Rougier P, Van Cutsem E. 1999 Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. Anti-Cancer Drugs. 10:617–623.
Ducreux M, Ychou M, Seitz JF, et al. 1999 Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol. 17:2901–2908.
Goldberg RM, Erlichman C. 1998 Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Oncology. 12:59–63.
Fuchs C, Miller L, Moore M, et al. 2000 Phase III comparison of two CPT-11 dosing regimens (weekly x 4 every-6-weeks Vs every-3-weeks) in second-line colorectal cancer (CRC) therapy: interim safety report [abstract]. Proc Am Soc Clin Oncol. 19:255a.
Freyer G, Rougier P, Bugat R, et al. 2000 Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer. 83:431–437.
Ychou M, Kramar A, Raoul J, et al. 2000 Final results of a study using CPT-11 high dose (500 mg/m2) as first line chemotherapy in patients with metastatic colorectal cancer (MCRC) [abstract]. Proc Am Soc Clin Oncol. 19: 249a.
Ford HE, Cunningham D, Ross PJ, et al. 2000 Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Br J Cancer. 83:146–152.
Wasserman E, Cuvier C, Lokiec F, et al. 1999 Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 17: 1751–1759.
Hejna M, Kostler WJ, Raderer M, et al. 2000 Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Anti-Cancer Drugs. 11:629–634.
Scheithauer W, Kornek GV, Raderer M, et al. 1999 Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol. 17:902–906.
Boku N, Ohtsu A, Shimada Y, et al. 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 17:319–323.
Shirao K, Shimada Y, Kondo H, et al. 1997 Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol. 15:921–927.
Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. 2001 Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology. 15:46–51.
Sanz-Altamira P, O’Reilly EM, Stuart K, et al. 2001 A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol. 12:501–504.
O’Reilly EM, Stuart K, Sanz-Altamira P, et al. 2001 A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer. 91:101–105.
Fukuoka M, Niitani H, Suzuki A, et al. 1992 A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 10:16–20.
Masuda N, Fukuoka M, Kusunoki Y, et al. 1992 CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 10:1225–1229.
Masuda N, Fukuoka M, Takada M, et al. 1992 CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol. 10:1775–1780.
Nakanishi Y, Takayama K, Takano K, et al. 1999 Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol. 22:399–402.
Fujita A, Takabatake H, Tagaki S, Sekine K. 2000 Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer. Cancer Chemother Pharmacol. 45:279–283.
Omura M, Torigoe S, Kubota N. 1997 SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiother Oncol. 43: 197–201.
Chen AY, Okunieff P, Pommier Y, Mitchell JB. 1997 Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 57:1529–1536.
Boothman DA, Wang M, Schea RA, Burrows HL, Strickfaden S, Owens JK. 1992 Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int J Rad Oncol Biol Phys. 24:939–948.
Takeda K, Negoro S, Kudoh S, et al. 1999 Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer. 79:1462–1467.
Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J. 1998 Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 34:71–75.
Masuda N, Matsui K, Negoro S, et al. 1998 Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 6:3329–3334.
Masuda N, Negoro S, Kudoh S, et al. 2000 Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J Clin Oncol. 18:2996–3003.
Adjei AA, Klein CE, Kastrissios H, et al. 2000 Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol. 18: 1116–1123.
Natale RB, Socinski M, Sandler A, Israel VP, Miller L. 2000 Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. Oncology. 14:29–34.
Friedman HS, Petros WP, Friedman AH, et al. 1999 Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 17:1516–1525.
Castellino RC, Elion GB, Keir ST, et al. 2000 Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts [published erratum appears in Cancer Chemother Pharmacol 2000;46(1):84]. Cancer Chemother Pharmacol. 45:345–349.
Coggins CA, Elion GB, Houghton PJ, et al. 1998 Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 41:485–490.
Patel V, Elion G, Houghton P, et al. 2000 Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 6:4154–4157.
Lhomme C, Fumoleau P, Fargeot P, et al. 1999 Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 17:3136–3142.
Verschraegen CF, Levy T, Kudelka AP, et al. 1997 Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 15:625–631.
Rosen LS. 1998 Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology. 12:103–109.
Blaney S, Berg SL, Pratt C, et al. 2001 A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 7:32–37.
Vassal G, Droz F, Frappaz D, et al. 1999 A phase I trial of irinotecan (CPT-11) in children [abstract]. Proc Am Soc Clin Oncol. 18:563a.
Vassal G, Pondarre C, Boland I, et al. 1998 Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie. 80:271–280.
Niwa K, Misao R, Hanabayashi T, et al. 1994 Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative. Jpn J Cancer Res. 85:869–874.
Giovanella BC, Stehlin JS, Wall ME, et al. 1989 DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 246:1046–1048.
Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. 1995 Topoisomerase Irelated parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55:2116–2121.
Husain I, Mohler JL, Seigler HF, Besterman JM. 1994 Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54:539–546.
McLeod HL, Keith WN. 1996 Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer. 74:508–512.
McLeod HL, Douglas F, Oates M, et al. 1994 Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer. 59:607–611.
Guichard S, Terret C, Hennebelle I, et al. 1999 CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer. 80:364–370.
Abbruzzese JL, Madden T, Sugarman SM, et al. 1996 Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res. 2:1489–1497.
Danks MK, Garrett KE, Marion RC, Whipple DO. 1996 Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res. 56:1664–1673.
Desai SD, Liu LF, Vazquez-Abad D, D’Arpa P. 1997 Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 272:24159–24164.
Salonga D, Danenberg KD, Johnson M, et al. 2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327.
Johnston PG, Lenz HJ, Leichman CG, et al. 1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55: 1407–1412.
Rivory LP, Robert J. 1995 Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ther. 68:269–296.
Guemei A, Cottrell J, Band R, et al. 2001 Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chemother Pharmacol. 47:283–290.
Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. 2000 Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60:1189–1192.
Rivory LP. 2000 Metabolism of CPT-11. Impact on activity. Ann N Y Acad Sci. 922:205–215.
Ahmed F, Vyas V, Cornfield A, et al. 1999 In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res. 19:2067–2071.
Kaneda N, Nagata H, Furuta T, Yokokura T. 1990 Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50:1715–1720.
Onishi Y, Oguro M, Kizaki H. 1997 A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11. Cancer Chemother Pharmacol. 39:473–478.
Dodds H, Clarke S, Findlay M, Bishop J, Robert J, Rivory L.2000 Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. Cancer Chemother Pharmacol. 45: 9–14.
Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. 1997 Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res. 3:1261–1266.
Sparreboom A, de Jonge MJ, de Bruijn P, et al. 1998 Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res. 4:2747–2754.
Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. 1998 Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther. 286:578–583.
Dodds H, Wunsch R, Gillam E, Rivory L. 1999 Further elucidation of the pathways involved in the catabolism of the camptothecin analogue irinotecan [abstract]. Proc Am Assoc Cancer Res. 40:110.
Lokiec F, du Sorbier BM, Sanderink GJ. 1996 Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res. 2:1943–1949.
Dodds HM, Robert J, Rivory LP. 1998 The detection of photodegradation products of irinotecan (CPT-11, Campto, Camptosar), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. J Pharm Biomed Anal. 17:785–792.
Iyer L, King CD, Whitington PF, et al. 1998 Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 101:847–854.
Rivory LP, Robert J. 1995 Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol. 36: 176–179.
Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. 1994 Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:3723–3725.
Canal P, Gay C, Dezeuze A, et al. 1996 Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 14:2688–2695.
Wasserman E, Myara A, Lokiec F, et al. 1998 Bilirubin (Bil) and SN-38 metabolism: pharmacodynamics of CPT-11 [abstract]. Proc Am Soc Clin Oncol. 7:185a.
Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T. 1993 Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica. 23:5–10.
Yokoi T, Narita M, Nagai E, Hagiwara H, Aburada M, Kamataki T. 1995 Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. Jpn J Cancer Res. 86:985–989.
Takasuna K, Kasai Y, Kitano Y, et al. 1995 Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res. 86:978–984.
Dodds H, Stewart CF, Cheshire PJ, Hanna SK, PJ H, Rivory LP. 2001 Primary versus secondary activation of CPT-11: a role for tumor glucuronidases? [abstract] Proc Am Assoc Cancer Res. 42:253.
Takahashi T, Fujiwara Y, Miyazaki M, et al. 1998 The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin (SN-38) resistance [abstract]. Proc Am Soc Clin Oncol. 17:185a.
Chu XY, Kato Y, Sugiyama Y. 1997 Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 57:1934–1938.
Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. 1997 Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther. 281:304–314.
Chu XY, Kato Y, Ueda K, et al. 1998 Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res.; 58:5137–5143.
Sugiyama Y, Kato Y, Chu X. 1998 Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol. 42:S44–S49.
Brangi M, Litman T, Ciotti M, et al. 1999 Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:5938–5946.
Litman T, Brangi M, Hudson E, et al. 2000 The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 113:2011–2021.
Schellens JH, Maliepaard M, Scheper RJ, et al. 2000 Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci. 922:188–194.
Blaney SM, Takimoto C, Murry DJ, et al. 1998 Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol. 41: 464–468.
Chabot GG. 1997 Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 33:245–259.
Chabot GG, Abigerges D, Catimel G, et al. 1995 Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 6:141–151.
Rivory LP, Chatelut E, Canal P, Mathieu Boue A, Robert J. 1994 Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 54: 6330–6333.
Sasaki Y, Yoshida Y, Sudoh K, et al. 1995 Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res. 86:111–116.
Herben V, Schellens J, Swart M, et al. 1999 Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol. 17:1897–1905.
Van Groeningen C, Van Der Vijgh W, Giaccone G, et al. 1997 Phase I clinical and pharmacokinetic study of 5 day CPT-11 hepatic arterial infusion (HAI) chemotherapy [abstract]. Proc Am Soc Clin Oncol. 16: 219a.
Burke TG, Mi Z. 1994 The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem. 37:40–46.
Takimoto C, Morrison G, Harold N, et al. 2000 Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol. 18:659–667.
Furman W, Stewart C, Poquette C, et al. 1999 Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 17:1815–1824.
Ma MK, Zamboni WC, Radomski KM, et al. 2000 Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res. 6: 813–819.
Vassal G, Santos A, Pein F, Frappaz D, Mignard D, Doz F. 1997 Pharmacokinetics of irinotecan (CPT-11) and its metabolites in children [abstract]. Proc Am Assoc Cancer Res. 38:79.
Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P, Sparreboom A. 2000 Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res. 6: 3451–3458.
Schaaf L, Ichhpurani N, Elfring G, Wolf D, Rothenberg M, Von Hoff D. 1997 Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 16:202a.
Rivory LP, Findlay M, Clarke S, Bishop J. 1998 Trace analysis of SN-38 in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 714:355–359.
Rivory LP, Clarke S, Bishop J, O’Donnell A, Emmett L, Findlay M. 1996 Irinotecan (CPT-11): a preliminary investigation of the relationship between trough concentrations of the active metabolite, SN-38, and toxicity. 10th NCI-EORTC Meeting.
Slatter JG, Schaaf LJ, Sams JP, et al. 2000 Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos. 28:423–433.
Kaneda N, Yokokura T. 1990 Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 50: 1721–1725.
Dodds HM, Craik DJ, Rivory LP. 1997 Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. J Pharm Sci. 86:1410–1416.
Iyer L, Hall D, Das S, et al. 1999 Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 65:576–582.
Wasserman E, Myara A, Lokiec F, et al. 1997 Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports. Ann Oncol. 8:1049–1051.
Ando Y, Saka H, Ando M, et al. 2000 Polymorphisms of UDP-glucuronosyl-transferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:6921–6926.
Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. 1998 UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol. 9:845–847.
Iyer L, Janisch L, Das S, et al. 2000 UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11) [abstract]. Proc Am Soc Clin Oncol. 19:178a.
Raymond E, Vernillet L, Boige V, et al. 1999 Phase I and pharmacokinetic (PK) study of irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction [abstract]. Proc Am Soc Clin Oncol. 18:165a.
Boige V, Vernillet L, Hua A, et al. 2000 Total plasma clearance of irinotecan (CPT-11) correlates with both alkaline phosphatase and bilirubin levels in patients with tumoral hepatic involvement [abstract]. Proc Am Assoc Cancer Res. 41:608.
Ong S, Clarke S, Bishop J, Dodds H, Rivory LP. 2001 Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anti-Cancer Drugs. 12:619–625.
Reid J, Buckner J, Schaaf L, et al. 1999 Pharmacokientics of irinotecan (CPT-11) in recurrent glioma patients: results of an NCCTG phase II trial [abstract]. Proc Am Soc Clin Oncol. 18:141a.
Kehrer DF, Verweij J, de Bruijn P, Sparreboom A. 2001 Modulation of irinotecan (CPT-11) metabolism in cancer patients by ketoconazole [abstract]. Proc Am Assoc Cancer Res. 42:538.
Gupta E, Safa AR, Wang X, Ratain MJ. 1996 Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 56:1309–1314.
Gupta E, Wang X, Ramirez J, Ratain MJ. 1997 Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 39:440–444.
de Jonge MJ, Verweij J, Planting AS, et al. 1999 Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. Clin Cancer Res. 5:2012–2017.
de Jonge MJ, Sparreboom A, Planting AS, et al. 2000 Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol. 18:187–194.
Saltz LB, Kanowitz J, Kemeny NE, et al. 1996 Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol. 14:2959–2967.
Negoro S, Fukuoka M, Masuda N, et al. 1991 Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 83: 1164–1168.
Gandia D, Abigerges D, Armand JP, et al. 1993 CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol. 11:196–197.
Dodds H, Rivory L. 1999 The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol. 56:1346–1353.
Valencak J, Raderer M, Kornek GV, Henja MH, Scheithauer W. 1998 Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst. 90:160.
Pitot HC. 1998 US pivotal studies of irinotecan in colorectal carcinoma. Oncology. 12:48–53.
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. 1972 Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 56:95–101.
Natelson EA, Giovanella BC, Verschraegen CF, et al. 1996 Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci. 803:224–230.
Creemers GJ, Gerrits CJ, Eckardt JR, et al. 1997 Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol. 15:1087–1093.
Rowinsky EK, Grochow LB, Hendricks CB, et al. 1992 Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol. 10:647–656.
Kantarjian HM, Beran M, Ellis A, et al. 1993 Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 81:1146–1151.
Kudelka AP, Tresukosol D, Edwards CL, et al. 1996 Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 14:1552–1557.
Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. 1993 Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res. 84:697–702.
Rougier P, Bugat R. 1996 CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol. 23:34–41.
Saliba F, Hagipantelli R, Misset JL, et al. 1998 Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol. 16: 2745–2751.
Kase Y, Hayakawa T, Aburada M, Komatsu Y, Kamataki T. 1997 Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol. 75:407–413.
Takasuna K, Hagiwara T, Hirohashi M, et al. 1996 Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56:3752–3757.
Takasuna K, Hagiwara T, Hirohashi M, et al. 1998 Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol. 42:280–286.
Schaaf L, Slatter J, Sams J, et al. 1999 Metabolism and excretion of irinotecan (CPT-11) following IV infusion of [14C]CPT-11 in patients with advanced solid tumor malignancy [abstract]. Proc Am Soc Clin Oncol. 18: 164a.
Lenfers BH, Loeffler TM, Droege CM, Hausamen TU. 1999 Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol. 10: 1251–1253.
Shinkai T, Arioka H, Kunikane H, et al. 1994 Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res. 54:2636–2642.
Sakai H, Diener M, Gartmann V, Takeguchi N. 1995 Eicosanoid-mediated Cl-secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn-Schmiedebergs Arch Pharmacol. 351:309–314.
Sakai H, Sato T, Hamada N, et al. 1997 Thromboxane A2, released by the antitumour drug irinotecan, is a novel stimulator of Cl-secretion in isolated rat colon. J Physiol. 505:133–144.
Goto S, Okutomi T, Suma Y, Kera J, Soma G, Takeuchi S. 1996 Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells. Anticancer Res. 16:2507–2511.
Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M. 2000 Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 356:566–567.
Cao S, Black JD, Troutt AB, Rustum YM. 1998 Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res. 58:3270–3274.
Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ. 1998 Prevention of intestinal toxic effects and intensification of irinotecan’s therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Clin Cancer Res. 4:2053–2063.
Shinohara H, Killion JJ, Bucana CD, Yano S, Fidler IJ. 1999 Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin Cancer Res. 5:2148–2156.
Savarese D, Al-Zoubi A, Boucher J. 2000 Glutamine for irinotecan diarrhea. J Clin Oncol. 18: 450–451.
Hardman WE, Moyer MP, Cameron IL. 1999 Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer. 81:440–448.
Michael M, Brittain M, Nagai J, et al. 2001 A phase II study of activated charcoal to prevent irinotecan (CPT-11) induced diarrhea [abstract]. Proc Am Soc Clin Oncol. 20:405a.
Zidan J, Haim N, Beny A, Stein M, Gez E, Kuten A. 2001 Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol. 12:227–229.
Ooms LA, Degryse AD, Janssen PA. 1984 Mechanisms of action of loperamide. Scand J Gastroenterol Supp. 96:145–155.
Nikolic-Tomasevic Z, Jelic S, Popov I, Radosavljevic D. 2000 Colorectal cancer: dilemmas regarding patient selection and toxicity prediction. J Chemother. 12:244–251.
van Groeningen C, Van der Vijgh W, Baars J, Stieltjes H, Huibregtse K, Pinedo H. 2000 Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin Cancer Res. 6: 1342–1346.
Miya T, Fujikawa R, Fukushima J, Nogami H, Koshiishi Y, Goya T. 1998 Bradycardia induced by irinotecan: a case report. Jpn J Clin Oncol. 28:709–711.
Boisseau M, Bugat R, Mahjoubi M. 1996 Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11). Eur J Cancer. 32A:737–738.
Gupta E, Mick R, Ramirez J, et al. 1997 Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 15:1502–1510.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Rivory, L.P. (2005). Irinotecan. In: Adams, V.R., Burke, T.G. (eds) Camptothecins in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-866-8:229
Download citation
DOI: https://doi.org/10.1385/1-59259-866-8:229
Publisher Name: Humana Press
Print ISBN: 978-1-58829-027-4
Online ISBN: 978-1-59259-866-3
eBook Packages: MedicineMedicine (R0)